Health Care Reform and Possible Effects on Innovative Therapies: Cancer as a Case Study : Hearing Before the Subcommittee on Technology, Environment, and Aviation of the Committee on Science, Space, and Technology, U.S. House of Representatives, One Hundred Third Congress, Second Session, February 2, 1994, Volume 4
United States, United States. Congress. House. Committee on Science, Space, and Technology. Subcommittee on Technology, Environment, and Aviation
U.S. Government Printing Office, 1994 - 198 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
administration AIDS American approval areas believe biotech biotechnology industry breakthrough drugs breast cancer cancer research capital cells Center Chairman changes clinical colon colorectal cancer committee companies competition concerns continue cost countries CURD cure disease doctors drug prices Duke Duke University effective example expensive fact FELDBAUM firms funding future gene going growth health care reform hearing hospital human impact important improve incidence increased innovation Institute investment investors issue Italy Japan less limit look mean medical device medicine million Oncology PASSE patients percent pharmaceutical President price controls problem proposed question raise reason recent reduce regulation result risk spending surgery Thank therapeutic therapies treat treatment trials tumor United University VALENTINE women
Page 77 - Never doubt that a small group of thoughtful committed citizens can change the world. Indeed it's the only thing that ever has.
Page 142 - The purpose of the Agency is to enhance the quality, appropriateness, and effectiveness of health care services, and access to such services, through the establishment of a broad base of scientific research and through the promotion of improvements in clinical practice (including the prevention of diseases and other health conditions) and in the organization, financing, and delivery of health care services.
Page 181 - R&D as a percent of sales for seven major drug companies is compared to Federal health care research spending as a percent of health care costs. This graph shows that major drug companies have doubled their...
Page 130 - Kaposi's sarcoma (KS) was examined with the use of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.
Page 54 - Reforms Needed in the Organization, Management, and Resources of the Food and Drug Administration's Center for Devices and Radiological Health.
Page 181 - One of out of every three living Americans will die of cancer. Currently, there are over 8 million cancer patients in the US You can think of them as having tested positive for cancer. I talk with hundreds of cancer patients every year. I get phone calls every day and I know their problems with the health care system. First, and foremost, they haven't got a cure for their disease.
Page 184 - Lower market value* mean that the cost of capital is going up and less capital is available. ultimately, capital flows are reflected in research budgets as well as in prices . As I mentioned, I have been involved in several high tech ventures. Currently* "word on the street...
Page 6 - I thank all of you for being here, and I look forward to hearing your testimony. Thank you, Mr. Chairman.
Page 69 - I would be pleased to answer any questions you might have. Thank you. [The prepared statement of Mr.